Form 8-K - Current report:
SEC Accession No. 0001193125-25-145742
Filing Date
2025-06-24
Accepted
2025-06-24 16:15:16
Documents
17
Period of Report
2025-06-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d885397d8k.htm   iXBRL 8-K 37122
2 EX-4.1 d885397dex41.htm EX-4.1 78631
3 EX-4.2 d885397dex42.htm EX-4.2 77916
4 EX-10.1 d885397dex101.htm EX-10.1 113080
5 EX-99.1 d885397dex991.htm EX-99.1 9390
9 GRAPHIC g885397g0624205043318.jpg GRAPHIC 3115
  Complete submission text file 0001193125-25-145742.txt   517767

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA jagx-20250624.xsd EX-101.SCH 2878
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20250624_lab.xml EX-101.LAB 17995
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20250624_pre.xml EX-101.PRE 11280
19 EXTRACTED XBRL INSTANCE DOCUMENT d885397d8k_htm.xml XML 3636
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 251069385
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)